Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Argenx Se ADR
(NQ:
ARGX
)
375.00
-0.08 (-0.02%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
266,420
Open
380.85
Bid (Size)
365.77 (1)
Ask (Size)
383.00 (1)
Prev. Close
375.08
Today's Range
372.68 - 380.85
52wk Range
327.73 - 550.76
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
The Analyst Verdict: argenx In The Eyes Of 12 Experts
April 18, 2024
Via
Benzinga
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
April 16, 2024
From
argenx SE
Via
GlobeNewswire
Performance
YTD
-1.57%
-1.57%
1 Month
-5.88%
-5.88%
3 Month
+1.38%
+1.38%
6 Month
-22.07%
-22.07%
1 Year
-4.12%
-4.12%
More News
Read More
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
April 10, 2024
Via
Benzinga
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
March 27, 2024
From
argenx SE
Via
GlobeNewswire
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
March 26, 2024
From
argenx SE
Via
GlobeNewswire
Key Takeaways From argenx Analyst Ratings
March 26, 2024
Via
Benzinga
Earnings Scheduled For February 29, 2024
February 29, 2024
Via
Benzinga
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
March 26, 2024
Via
Benzinga
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
March 26, 2024
From
argenx SE
Via
GlobeNewswire
Guess? Posts Upbeat Earnings, Joins Lufax, Nortech Systems And Other Big Stocks Moving Higher On Thursday
March 21, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday?
March 21, 2024
Via
Benzinga
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 21, 2024
Via
Benzinga
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
March 21, 2024
Via
Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
March 21, 2024
Via
Benzinga
Why Micron Therapies Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
March 21, 2024
Via
Benzinga
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
March 07, 2024
From
argenx SE
Via
GlobeNewswire
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
February 29, 2024
From
argenx SE
Via
GlobeNewswire
argenx to Present at Upcoming Investor Conferences
February 26, 2024
From
argenx SE
Via
GlobeNewswire
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
February 22, 2024
From
argenx SE
Via
GlobeNewswire
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
February 21, 2024
Via
InvestorPlace
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
February 20, 2024
From
argenx SE
Via
GlobeNewswire
5 medical stocks growing earnings by triple digits
February 06, 2024
Via
MarketBeat
Topics
Economy
Exposures
Economy
New Hope For Patients With Chronic Autoimmune Conditions: Johnson & Johnson's Investigational Drug Meets Primary Goal In Two Studies
February 05, 2024
Via
Benzinga
Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion
January 18, 2024
Via
Benzinga
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
January 18, 2024
From
argenx SE
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.